CF PharmTech, Inc. (stock code 02652) repurchased 10,500 of its H shares on 10 February 2026. The highest and lowest repurchase prices were HKD 35.66 and HKD 35.18 per share, respectively, for a total aggregate cost of HKD 370,460. Following this transaction, the total number of ordinary shares outstanding now stands at 301,999,586, while the number of treasury shares has increased to 224,000.

The company’s repurchase mandate, approved on 16 December 2025, authorizes the buyback of up to 30,222,358 shares. To date, 224,000 shares—equal to approximately 0.0741% of the issued shares (excluding treasury shares) as at the date of the resolution—have been repurchased. Under the rules governing repurchases, there is a moratorium on any new share issue or sale/transfer of treasury shares until 12 March 2026.